No Data
No Data
AlphaValue/Baader Europe Notes GSK's 'Healthy' Start to FY25 After Q1 Beat
FDA to Tighten Vaccine Approval Requirements: Reports
Trump Administration Said to Be Investing $500M on Developing Universal Vaccines
Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
Research Alert: CFRA Keeps Hold Opinion On Adss Of Gsk
GSK Plc (GSK) Q1 2025 Earnings Conference Call Transcript Summary
frankinglily : GSK's specialty growth sounds promising.![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
Shaaaw : Mixed analyst ratings have me cautious.